Relief of Bleeding on the Implant: Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With a Combined Oral Contraceptive: A Placebo-Controlled Randomized Trial
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 26
- 试验地点
- 2
- 主要终点
- Number of Participants With Bleeding Improvement
研究概览
简要总结
This double-blinded, placebo-controlled, randomized trial will compare the effects of the use of a combined oral contraceptive pill to a placebo pill for women who are experiencing irregular and/or heavy bleeding associated with the use of an etonogestrel (ETG) implant.
The hypothesis of the study is:
- Use of combined oral contraceptive will significantly improve bleeding patterns for users of ETG implant
- Continuation rate of ETG implant users will be increased by use of combined oral contraceptive in women desiring ETG implant removal because of the undesirable bleeding
- Adverse events will be uncommon and acceptable to women who use a combined oral contraceptive with the ETG implant
详细描述
Women who are experiencing irregular and/or heavy bleeding associated with the use of an etonogestrel (ETG) implant will be recruited for this study. Women who have bothersome bleeding will be randomized to use either a combined oral contraceptive pill or a placebo pill.
Participants will take one pill every day and record their bleeding patterns on a daily diary.
Participants will have one screening/enrollment visit, two in-person follow up visits, and one telephone follow up contact. Subjects will be enrolled for a total of 84 days (three months).
Participants will be assigned to a treatment group at her screening/enrollment visit. Her first follow up visit will occur 22-28 days after her enrollment. Participants can choose to:
- Continue use of assigned treatment medication
- Discontinue use of assigned treatment medication, but use an open-label combined oral contraceptive pill
- Discontinue the use of assigned treatment medication, decline use of an open-label combined oral contraceptive pill
- Discontinue use of ETG implant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 14 Years 至 —（Child, Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women who have an ETG implant in place
- •Women who subjectively experience the side effect of an undesirable bleeding profile such as bleeding irregularity or heavy flow after ETG implant was placed and who desire intervention for this side effect by either treatment of bleeding or removal of the implant
- •Age 14 years an older, inclusive
排除标准
- •Irregular or heavy bleeding from an etiology other than ETG use (e.g. fibroids, cervical polyp, or other organic cause of bleeding)
- •Has attempted prescription treatment for menstrual side effects while using ETG implant
- •Has one or more of the conditions considered Category 3 (risks outweigh benefits) or Category 4 (unacceptable health risk) for estrogen-containing oral contraceptives by the Center for Disease Control Medical Eligibility Criteria for Contraceptive Use:
- •Current or history of heart or vascular diseases, including deep venous thrombosis, pulmonary embolism, known thrombogenic mutations, peripartum cardiomyopathy, and complicated valvular heart disease
- •Hypertension, even if adequately controlled
- •Diabetes with vascular involvement
- •Headaches with focal aura, or migraines in women age 35 and older even without focal aura
- •Major surgery with prolonged immobilization
- •Breast cancer (current or past)
- •Severe (decompensated) cirrhosis
- •Acute or flare viral hepatitis
- •Breastfeeding less than 1 month postpartum
- •Post-partum less than 3 weeks
- •35 years of age and older and smoking
- •Multiple risk factors for arterial cardiovascular disease
- •Systemic Lupus Erythematosus with positive or unknown antiphospholipid antibodies
- •Current symptomatic gallbladder disease or history of cholestasis related to past combined oral contraceptive use
- •On certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine, lamotrigine)
- •On Ritonavir-boosted protease inhibitors for antiretroviral therapy
- •Issues or concerns, in the judgment of the investigator, that may compromise the safety of the subject, impact the subject's adherence to the protocol requirements, or confound the reliability of the data acquired in this study
研究组 & 干预措施
EE 30mcg/LNG 150mcg
combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
干预措施: EE 30mcg/LNG 150mcg (Drug)
Placebo
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants With Bleeding Improvement
时间窗: Bleeding improvement will be evaluated during first cycle of study treatment (28 days)
Bleeding improvement will be measured by participant response to the question of whether she feels her bleeding is improved and she is satisfied with the treatment.
次要结局
- Number of Participants With Adverse Events(Adverse events will be evaluated at each contact (visits at 1 and 3 months, phone contact at 2 months) with the participant)
研究者
Mitchell Creinin, MD
Professor and Director of Family Planning
University of California, Davis